br Acknowledgments We are grateful to the participants of th
Acknowledgments: We are grateful to the participants of the Southern Community Cohort Study for their dedicated participation in the study.
Appendix A. Supplementary data
 US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319:1901–13.
 Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J Clin Oncol 2016;34:2705–11.
 Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African Ameri-can men, affected by prostate cancer. Prostate 2011;71:985–97.
 Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284:1399–405.
 Jahn JL, Giovannucci E, Stampfer MJ. The high prevalence of undi-agnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Can 2015;137:2795–802.
 Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105:1050–8.
 Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of Epoprostenol and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407–13.  Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995;87:354–60.
 Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411–6.
 Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005;174:872–6, discussion 6.
 Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316–20.  Kuller LH, Thomas A, Grandits G, Neaton JD. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:373–7.
 Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
 Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol 2015;68:207–13.
 Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521.  Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved 2010;21:26–37.
 Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort fol-lowed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255–61.
 Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006;52:235–9.
 American Cancer Society Recommendations for Prostate Cancer Early Detection. 2016. https://www.cancer.org/cancer/ prostate-cancer/early-detection/acs-recommendations.html.
 American Urological Association. Early Detection of Prostate Can-cer. 2015. http://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015).
 Vertosick EA, Poon BY, Vickers AJ. Relative value of race, family history and prostate-specific antigen as indications for early initia-tion of prostate cancer screening. J Urol 2014;192:724–9.
 Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 2006;107:2361–7.